A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma - Contacts and Locations

A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

This study is currently recruiting participants.
Information provided by GlaxoSmithKline

Please refer to this study by its ClinicalTrials.gov identifier: NCT00315731

Locations


United States, Florida
	GSK Clincial Trials Call Center	Active, not recruiting
	Bay Pines, Florida, United States, 33708

United States, Illinois
	GSK Clinical Trials Call Center	Recruiting
	Chicago, Illinois, United States, 60612
	Contact: Stephanie Gregory 877-379-3718

United States, Michigan
	GSK Clinical Trials Call Center	Active, not recruiting
	Ann Arbor, Michigan, United States, 48109

United States, Nebraska
	GSK Clinical Trials Call Center	Recruiting
	Omaha, Nebraska, United States, 68198
	Contact: Julie Vose 877-379-3718

United States, North Carolina
	GSK Clinical Trials Call Center	Recruiting
	Durham, North Carolina, United States, 27710
	Contact: Joe Gockerman 877-379-3718

United States, Pennsylvania
	GSK Clinical Trials Call Center	Active, not recruiting
	Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

GlaxoSmithKline

Investigators


Study Director:	GSK Clinical Trials, MD	GlaxoSmithKline